CLL Coverage from Every Angle

Paolo Ghia, MD, PhD, on Clinical Implications of Treating CLL/SLL With Ibrutinib Plus Venetoclax

Posted: Tuesday, June 22, 2021

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the clinical significance of findings from the CAPTIVATE study, which showed that an all-oral, chemotherapy-free regimen of ibrutinib plus venetoclax may benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Ghia also talks about what can be achieved in terms of treatment-free remission.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.